Evan S Dellon1, John T Woosley2, Ashley Arrington3, Sarah J McGee3, Jacquelyn Covington3, Susan E Moist3, Jessica H Gebhart3, Alexandra E Tylicki3, Shiyan O Shoyoye3, Christopher F Martin3, Joseph A Galanko3, John A Baron3, Nicholas J Shaheen3. 1. Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. Electronic address: edellon@med.unc.edu. 2. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 3. Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Abstract
BACKGROUND AND AIMS: Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed fluticasone from a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, but the 2 have never been compared. We assessed whether OVB was more effective than MDI for initial treatment of patients with EoE. METHODS: In a double-blind, double-dummy trial, patients with a new diagnosis of EoE were randomly assigned to groups given 8 weeks of either OVB (1 mg/4 mL) twice daily plus a placebo inhaler (n = 56) or fluticasone MDI (880 μg) twice daily plus a placebo slurry (n = 55). Primary outcomes were post-treatment maximum eosinophil counts per high-power field (eos/hpf) and a validated dysphagia score (dysphagia symptom questionnaire [DSQ]) at week 8. Secondary outcomes included endoscopic severity (validated EoE endoscopic reference score), histologic response (<15 eos/hpf), and safety. RESULTS: In a modified intention-to-treat analysis, the subjects had baseline peak eosinophil counts of 73 and 77 eos/hpf in the OVB and MDI groups, respectively, and DSQ scores of 11 and 8. Post-treatment eosinophil counts were 15 and 21 in the OVB and MDI groups, respectively (P = .31), with 71% and 64% achieving histologic response (P = .38). DSQ scores were 5 and 4 in the OVB and MDI groups (P = .70). Similar trends were noted for post-treatment total EoE endoscopic reference scores (2 vs 3; P = .06). Esophageal candidiasis developed in 12% of patients receiving OVB and 16% receiving MDI; oral thrush was observed in 3% and 2%, respectively. CONCLUSIONS: In a randomized clinical trial, initial treatment of EoE with either OVB or fluticasone MDI produced a significant decrease in esophageal eosinophil counts and improved dysphagia and endoscopic features. However, OVB was not superior to MDI, so either is an acceptable treatment for EoE. ClinicalTrials.gov ID NCT02019758.
RCT Entities:
BACKGROUND AND AIMS: Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed fluticasone from a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, but the 2 have never been compared. We assessed whether OVB was more effective than MDI for initial treatment of patients with EoE. METHODS: In a double-blind, double-dummy trial, patients with a new diagnosis of EoE were randomly assigned to groups given 8 weeks of either OVB (1 mg/4 mL) twice daily plus a placebo inhaler (n = 56) or fluticasone MDI (880 μg) twice daily plus a placebo slurry (n = 55). Primary outcomes were post-treatment maximum eosinophil counts per high-power field (eos/hpf) and a validated dysphagia score (dysphagia symptom questionnaire [DSQ]) at week 8. Secondary outcomes included endoscopic severity (validated EoE endoscopic reference score), histologic response (<15 eos/hpf), and safety. RESULTS: In a modified intention-to-treat analysis, the subjects had baseline peak eosinophil counts of 73 and 77 eos/hpf in the OVB and MDI groups, respectively, and DSQ scores of 11 and 8. Post-treatment eosinophil counts were 15 and 21 in the OVB and MDI groups, respectively (P = .31), with 71% and 64% achieving histologic response (P = .38). DSQ scores were 5 and 4 in the OVB and MDI groups (P = .70). Similar trends were noted for post-treatment total EoE endoscopic reference scores (2 vs 3; P = .06). Esophageal candidiasis developed in 12% of patients receiving OVB and 16% receiving MDI; oral thrush was observed in 3% and 2%, respectively. CONCLUSIONS: In a randomized clinical trial, initial treatment of EoE with either OVB or fluticasone MDI produced a significant decrease in esophageal eosinophil counts and improved dysphagia and endoscopic features. However, OVB was not superior to MDI, so either is an acceptable treatment for EoE. ClinicalTrials.gov ID NCT02019758.
Authors: Elizabeth T Jensen; Michael D Kappelman; Christopher F Martin; Evan S Dellon Journal: Am J Gastroenterol Date: 2014-09-30 Impact factor: 10.864
Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793
Authors: Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta Journal: Clin Gastroenterol Hepatol Date: 2008-02 Impact factor: 11.382
Authors: Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Glenn T Furuta; Chris A Liacouras; David A Katzka Journal: Am J Gastroenterol Date: 2013-04-09 Impact factor: 10.864
Authors: Evan S Dellon; Arif Sheikh; Olga Speck; Kimberly Woodward; Ann B Whitlow; Jessica M Hores; Marija Ivanovic; Allen Chau; John T Woosley; Ryan D Madanick; Roy C Orlando; Nicholas J Shaheen Journal: Gastroenterology Date: 2012-05-03 Impact factor: 22.682
Authors: Stephan Miehlke; Petr Hruz; Michael Vieth; Christian Bussmann; Ulrike von Arnim; Monther Bajbouj; Christoph Schlag; Ahmed Madisch; Christiane Fibbe; Henning Wittenburg; Hans Dieter Allescher; Max Reinshagen; Stefan Schubert; Jan Tack; Michaela Müller; Patrick Krummenerl; Joris Arts; Ralph Mueller; Karin Dilger; Roland Greinwald; Alex Straumann Journal: Gut Date: 2015-03-19 Impact factor: 23.059
Authors: Ian F Slack; Justin T Schwartz; Vincent A Mukkada; Shawna Hottinger; J Pablo Abonia Journal: Curr Allergy Asthma Rep Date: 2020-06-06 Impact factor: 4.806
Authors: Evan S Dellon; John T Woosley; Ashley Arrington; Sarah J McGee; Jacquelyn Covington; Susan E Moist; Jessica H Gebhart; Joseph A Galanko; John A Baron; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2019-09-06 Impact factor: 11.382
Authors: Swathi Eluri; Edward G A Iglesia; Michael Massaro; Anne F Peery; Nicholas J Shaheen; Evan S Dellon Journal: Dis Esophagus Date: 2020-05-07 Impact factor: 3.429
Authors: Christopher Ma; Alain M Schoepfer; Evan S Dellon; Albert J Bredenoord; Mirna Chehade; Margaret H Collins; Brian G Feagan; Glenn T Furuta; Sandeep K Gupta; Ikuo Hirano; Vipul Jairath; David A Katzka; Rish K Pai; Marc E Rothenberg; Alex Straumann; Seema S Aceves; Jeffrey A Alexander; Nicoleta C Arva; Dan Atkins; Luc Biedermann; Carine Blanchard; Antonella Cianferoni; Constanza Ciriza de Los Rios; Frederic Clayton; Carla M Davis; Nicola de Bortoli; Jorge A Dias; Gary W Falk; Robert M Genta; Gisoo Ghaffari; Nirmala Gonsalves; Thomas Greuter; Russell Hopp; Karen S Hsu Blatman; Elizabeth T Jensen; Doug Johnston; Amir F Kagalwalla; Helen M Larsson; John Leung; Hubert Louis; Joanne C Masterson; Calies Menard-Katcher; Paul A Menard-Katcher; Fouad J Moawad; Amanda B Muir; Vincent A Mukkada; Roberto Penagini; Robert D Pesek; Kathryn Peterson; Philip E Putnam; Alberto Ravelli; Edoardo V Savarino; Christoph Schlag; Philipp Schreiner; Dagmar Simon; Thomas C Smyrk; Jonathan M Spergel; Tiffany H Taft; Ingrid Terreehorst; Tim Vanuytsel; Carina Venter; Mario C Vieira; Michael Vieth; Berber Vlieg-Boerstra; Ulrike von Arnim; Marjorie M Walker; Joshua B Wechsler; Philip Woodland; John T Woosley; Guang-Yu Yang; Noam Zevit; Ekaterina Safroneeva Journal: J Allergy Clin Immunol Date: 2021-07-06 Impact factor: 10.793
Authors: Thomas Greuter; Anne Godat; Amit Ringel; Hector Samuel Almonte; Daniel Schupack; Gabriela Mendoza; Talaya McCright-Gill; Evan S Dellon; Ikuo Hirano; Jeffrey Alexander; Mirna Chehade; Ekaterina Safroneeva; Christian Bussmann; Luc Biedermann; Philipp Schreiner; Alain M Schoepfer; Alex Straumann; David A Katzka Journal: Clin Gastroenterol Hepatol Date: 2020-08-13 Impact factor: 11.382